Patterns of Nonadherence to Antihypertensive Therapy in Primary Care

Journal of Clinical Hypertension

Volumn 15, Issue 2, 2013, Pages 107-111

  Grigoryan, Larissa ^a   Pavlik, Valory N ^a   Hyman, David J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AFRICAN AMERICAN; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PRIVATE PRACTICE;

ADULT; AFRICAN AMERICANS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84872677138     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12030     Document Type: Article

References (22)

1. Moser M, Setaro JF. Clinical practice. Resistant or difficult-to-control hypertension. N Engl J Med. 2006;355:385-392.
2. Shah NR, Hirsch AG, Zacker C, et al. Predictors of first-fill adherence for patients with hypertension. Am J Hypertens. 2009;22:392-396.
3. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521-530.
4. Sabate E. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003. http://apps.who.int/medicinedocs/en/d/Js4883e. Accessed August 22, 2012.
5. Rose AJ, Berlowitz DR, Manze M, et al. Intensifying therapy for hypertension despite suboptimal adherence. Hypertension. 2009;54:524-529.
6. Rose AJ, Glickman ME, D'Amore MM, et al. Effects of daily adherence to antihypertensive medication on blood pressure control. J Clin Hypertens (Greenwich). 2011;13:416-421.
7. Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336:1114-1117.
8. Burnier M. Compliance in hypertension. EDTNA ERCA J. 2005;31:152-155.
9. Lowy A, Munk VC, Ong SH, et al. Effects on blood pressure and cardiovascular risk of variations in patients' adherence to prescribed antihypertensive drugs: role of duration of drug action. Int J Clin Pract. 2011;65:41-53.
10. Pavlik VN, Greisinger AJ, Pool J, et al. Does reducing physician uncertainty improve hypertension control?: rationale and methods. Circ Cardiovasc Qual Outcomes. 2009;2:257-263.
11. Hyman DJ, Pavlik VN, Greisinger AJ, et al. Effect of a physician uncertainty reduction intervention on blood pressure in uncontrolled hypertensives - a cluster randomized trial. J Gen Intern Med. 2012;27:413-419.
12. Riekert KA, Rand CS. Electronic monitoring of medication adherence: when is high-tech best?J Clin Psychol Med Settings. 2002;9:25-34.
13. Biston P, Melot C, Degaute JP, et al. Prolonged antihypertensive effect of amlodipine: a prospective double-blind randomized study. Blood Press. 1999;8:43-48.
14. Leenen FH, Fourney A, Notman G, Tanner J. Persistence of anti-hypertensive effect after 'missed doses' of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half-life. Br J Clin Pharmacol. 1996;41:83-88.
15. Elliott HL, Elawad M, Wilkinson R, Singh SP. Persistence of antihypertensive efficacy after missed doses: comparison of amlodipine and nifedipine gastrointestinal therapeutic system. J Hypertens. 2002;20:333-338.
16. Hernandez RH, Armas-Hernandez MJ, Chourio JA, et al. Comparative effects of amlodipine and nifedipine GITS during treatment and after missing two doses. Blood press Monit. 2001;6:47-57.
17. Dorsch MP, Gillespie BW, Erickson SR, et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension. 2011;57:689-694.
18. Rosendorff C. Why are we still using hydrochlorothiazide?J Clin Hypertens (Greenwich). 2011;13:867-869.
19. Flack JM, Sica DA, Nesbitt S. Chlorthalidone versus hydrochlorothiazide as the preferred diuretic: is there a verdict yet?Hypertension. 2011;57:665-666.
20. Mensah GA, Mokdad AH, Ford ES, et al. State of disparities in cardiovascular health in the United States. Circulation. 2005;111:1233-1241.
21. Ogedegbe G, Chaplin W, Schoenthaler A, et al. A practice-based trial of motivational interviewing and adherence in hypertensive African Americans. Am J Hypertens. 2008;21:1137-1143.
22. Grigoryan L, Pavlik VN, Hyman DJ. Predictors of antihypertensive medication adherence in two urban health-care systems. Am J Hypertens. 2012;25:735-738.